Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells

[1]  Zhiqiang Wu,et al.  Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies , 2022, Signal Transduction and Targeted Therapy.

[2]  A. Regev,et al.  A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  J. Lieberman,et al.  Gasdermin E suppresses tumor growth by activating anti-tumor immunity , 2020, Nature.

[4]  A. Chinnaiyan,et al.  CD8+ T cells regulate tumor ferroptosis during cancer immunotherapy , 2019, Nature.

[5]  N. Bowden,et al.  BCL-2 family isoforms in apoptosis and cancer , 2019, Cell Death & Disease.

[6]  M. Solh,et al.  Chimeric Antigen Receptor T-Cells: The Future Is Now , 2019, Journal of clinical medicine.

[7]  N. Hamerschlak,et al.  BCL-2 as therapeutic target for hematological malignancies , 2018, Journal of Hematology & Oncology.

[8]  N. Aguiló,et al.  Antigen-specific primed cytotoxic T cells eliminate tumour cells in vivo and prevent tumour development, regardless of the presence of anti-apoptotic mutations conferring drug resistance , 2018, Cell Death & Differentiation.

[9]  Elizabeth J. Osterlund,et al.  BCL-2 family proteins: changing partners in the dance towards death , 2017, Cell Death and Differentiation.

[10]  D. Green,et al.  MOMP, cell suicide as a BCL-2 family business , 2017, Cell Death and Differentiation.

[11]  A. Letai,et al.  iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry , 2016, Biological chemistry.

[12]  M. Vemuri,et al.  CAR T Cell Therapy: A Game Changer in Cancer Treatment , 2016, Journal of immunology research.

[13]  A. Letai,et al.  Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines , 2016, Oncotarget.

[14]  D. Green,et al.  Cell Death Signaling. , 2015, Cold Spring Harbor perspectives in biology.

[15]  Karen Cichowski,et al.  Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.

[16]  S. Karlsson,et al.  Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy , 2013, Cancer Gene Therapy.

[17]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[18]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[19]  H. Walczak,et al.  Caspase-8 and bid: caught in the act between death receptors and mitochondria. , 2011, Biochimica et biophysica acta.

[20]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[21]  Christoph Borner,et al.  XIAP discriminates between type I and type II FAS-induced apoptosis , 2009, Nature.

[22]  John Calvin Reed,et al.  Bcl-2 family proteins and cancer , 2008, Oncogene.

[23]  C. Borner,et al.  Granzyme B-induced cell death exerted by ex vivo CTL: discriminating requirements for cell death and some of its signs , 2008, Cell Death and Differentiation.

[24]  James C. Whisstock,et al.  The major human and mouse granzymes are structurally and functionally divergent , 2006, The Journal of cell biology.

[25]  R. Sabirov,et al.  Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase , 2005, Cell Death and Differentiation.

[26]  D. Green,et al.  Granzyme B–Mediated Cytochrome C Release Is Regulated by the Bcl-2 Family Members Bid and Bax , 2000, The Journal of experimental medicine.